Key Takeaways
- Valuation disparities between US and Chinese equities are starkly illustrated in recent analyst estimates, highlighting a strong conviction in a Chinese re-rating despite significant geopolitical and economic risks.
- The bull case for PDD Holdings is underpinned by phenomenal revenue growth, but its lofty price target requires sustained, likely unrealistic, performance and margin stability amidst fierce competition.
- Alibaba’s value proposition is hampered by persistent execution risks and a ‘geopolitical discount’, making its deeply discounted valuation a potential value trap rather than a straightforward opportunity.
- Estimates for US firms like UnitedHealth and Meta appear more grounded in sector-specific dynamics, questioning the bullish healthcare outlook while affirming a ‘fully priced’ narrative for mega-cap tech.
The exercise of publishing one’s own fair value estimates is a bold one, inviting scrutiny and forcing a clear articulation of a thesis. A recent list of such estimates from analyst Natan (@nataninvesting) offers a compelling snapshot of market sentiment, revealing a particularly aggressive optimism for Chinese technology stocks alongside a more measured, and at times bearish, view on their US counterparts. This analysis moves beyond the headline numbers to dissect the underlying assumptions for companies like PDD Holdings, Alibaba, UnitedHealth, and Robinhood, stress-testing whether these valuations can withstand fundamental pressures and the prevailing macroeconomic climate.
The estimates propose considerable upside for certain names, such as a 65% potential gain for PDD and 42% for Alibaba, while suggesting a modest 3% upside for Meta and an 11% downside for Robinhood. This divergence is not merely a collection of stock picks; it is a commentary on perceived mispricings between two of the world’s largest economies and a bet on where capital flows may be heading next.
The Great Chinese Re-Rating Bet
The most striking feature of the valuation list is its profound bullishness on Chinese e-commerce platforms. The targets for both PDD Holdings and Alibaba are not merely optimistic; they imply a fundamental re-evaluation of Chinese equities by the broader market, an event that has been anticipated for years but has consistently failed to materialise.
PDD Holdings: Pricing in Perfection?
A fair value of $173 for PDD Holdings suggests a belief that its spectacular growth trajectory is far from over. The company’s performance has indeed been remarkable, with revenue surging 131% year-over-year in the first quarter of 2024, driven by its domestic platform Pinduoduo and the aggressive international expansion of Temu. [1] Proponents argue that its current forward price-to-earnings ratio, hovering in the mid-teens, does not adequately reflect this hyper-growth profile, especially when compared to global technology peers.
However, a target this high requires more than just continued growth; it requires perfection. It assumes that PDD can maintain its momentum against intense competition from Alibaba and ByteDance’s Douyin, that its notoriously thin margins can expand, and that the geopolitical tensions casting a shadow over all Chinese firms will dissipate. The reliance on heavy marketing spend and subsidies to fuel growth remains a significant question mark over the long-term profitability and sustainability of its model. The $173 price point seems to discount these risks almost entirely.
Alibaba: A Value Trap in Waiting?
In contrast to PDD’s growth narrative, the case for Alibaba at $162 is a value-based argument. With a single-digit P/E ratio, the company appears deeply undervalued on paper. [2] The thesis rests on a successful corporate restructuring and the market eventually recognising the sum-of-the-parts value of its cloud, logistics, and international commerce arms. Yet, this view may be overlooking the forest for the trees.
Alibaba’s path has been fraught with difficulty. The company has struggled with a legacy of regulatory crackdowns and has fumbled key strategic moves, such as the cancellation of IPOs for its Cainiao logistics and Cloud Intelligence units. More importantly, its core domestic commerce business is facing structural, not cyclical, challenges. Ascribing a valuation that is more than double its current market capitalisation seems to ignore the persistent ‘geopolitical discount’ and governance concerns that have deterred global investors. Without a clear catalyst to unlock that value, Alibaba risks remaining a textbook value trap.
A Sober Assessment of US Markets
The valuations for the US-listed companies in the portfolio paint a more nuanced and arguably more realistic picture, reflecting an awareness of sector-specific headwinds and mature market dynamics.
The table below summarises the key valuation estimates and the context surrounding them. Note that current prices are approximate as of the time of writing and are subject to market fluctuation.
| Company | Ticker | Fair Value Estimate | Implied Upside/Downside | Key Analytical Consideration |
|---|---|---|---|---|
| PDD Holdings | $PDD | $173 | ~+65% | Thesis depends on sustained hyper-growth and margin expansion. |
| Alibaba Group | $BABA | $162 | ~+42% | A deep value play hampered by execution risk and geopolitical factors. |
| UnitedHealth Group | $UNH | $450 | ~+41% | Contrarian bull case against rising medical cost trends. |
| PayPal Holdings | $PYPL | $103 | ~+37% | Bet on a successful turnaround under new leadership. |
| TransMedics Group | $TMDX | $162 | ~+23% | Growth priced in, but upside remains if execution continues. |
| Meta Platforms | $META | $752 | ~+3% | Effectively a ‘hold’ rating, suggesting the market has it right. |
| Robinhood Markets | $HOOD | $85 | ~-11% | Bearish view on a stock reliant on volatile retail and crypto activity. |
Sector Headwinds and Fair Valuations
The target of $450 for UnitedHealth, implying a 41% upside, is a notably contrarian call. The entire managed care industry is currently grappling with rising medical loss ratios (MLRs) as patients return for procedures deferred during the pandemic. UnitedHealth’s own MLR rose to 84.3% in its first quarter, a sign of increasing cost pressures that have weighed on the sector. [3] A bullish stance is a bet that these trends are temporary and that the company’s scale will allow it to navigate the pressure better than its peers, an outcome that is far from certain.
The minimal upside suggested for Meta Platforms aligns with a broad consensus that the company is now fairly valued. The market has already priced in the benefits of its “year of efficiency” and its strong position in the AI race. [4] Future growth must now contend with enormous capital expenditure requirements for AI and the metaverse, alongside persistent regulatory threats.
Finally, the bearish outlook for Robinhood stands out. While the firm has benefited from the recent revival in cryptocurrency trading and retail market engagement, the valuation implies a belief that this enthusiasm is unsustainable. It is a sober reminder that Robinhood’s fortunes are intrinsically tied to market volatility and sentiment, making its earnings stream less predictable than more established financial institutions.
Conclusion: A Tale of Two Markets
Ultimately, these fair value estimates tell a story of conviction. The conviction is that Chinese equities are poised for a significant recovery, justifying high-risk bets on names like PDD and Alibaba. At the same time, the analysis of US markets is more discerning, acknowledging that many opportunities have already been priced in and that sector-specific risks cannot be ignored.
While the potential for a Chinese re-rating is tantalising, a speculative hypothesis worth considering is that the very structure of the market prevents it. The ‘un-investability’ argument, driven by geopolitical risk and opaque governance, may represent a permanent discount factor that no amount of revenue growth or low earnings multiples can overcome. If that is the case, the real mispricing may not be the upside in Chinese stocks, but rather the market’s efficient pricing of the significant, non-financial risks involved in owning them.
References
[1] PDD Holdings. (2024, May 22). PDD Holdings Announces First Quarter 2024 Unaudited Financial Results. GlobeNewswire. Retrieved from financial statements related to PDD’s Q1 2024 performance.
[2] Simply Wall St. (2024). Alibaba Group Holding (NYSE:BABA) Stock Valuation. Retrieved from analysis on BABA’s valuation metrics.
[3] UnitedHealth Group. (2024, April 16). UnitedHealth Group Reports First Quarter 2024 Performance. Retrieved from UNH’s Q1 2024 earnings release detailing Medical Care Ratio.
[4] Nasdaq. (2024). Prediction: These 2 Artificial Intelligence (AI) Stocks Will Be the World’s Most Valuable Companies by 2035. Retrieved from general market commentary on AI stock valuations.
@nataninvesting. (2024, November 1). [Fair value estimates for portfolio companies including PDD, BABA, META]. Retrieved from https://x.com/nataninvesting/status/1858204801890210219
